220 related articles for article (PubMed ID: 1946598)
1. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
[TBL] [Abstract][Full Text] [Related]
2. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
[TBL] [Abstract][Full Text] [Related]
3. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.
Shebuski RJ; Ramjit DR; Sitko GR; Lumma PK; Garsky VM
Thromb Haemost; 1990 Dec; 64(4):576-81. PubMed ID: 2084943
[TBL] [Abstract][Full Text] [Related]
4. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
6. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
7. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time.
Tschopp JF; Driscoll EM; Mu DX; Black SC; Pierschbacher MD; Lucchesi BR
Coron Artery Dis; 1993 Sep; 4(9):809-17. PubMed ID: 8287215
[TBL] [Abstract][Full Text] [Related]
9. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
[TBL] [Abstract][Full Text] [Related]
10. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
[TBL] [Abstract][Full Text] [Related]
11. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
12. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
Shebuski RJ; Sitko GR; Claremon DA; Baldwin JJ; Remy DC; Stern AM
Blood; 1990 Apr; 75(7):1455-9. PubMed ID: 1969293
[TBL] [Abstract][Full Text] [Related]
16. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
17. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
Mehta JL; Nichols WW; Saldeen TG; Chandna VK; Nicolini FA; Lawson DL; ter Riet MF
J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
[TBL] [Abstract][Full Text] [Related]
18. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
19. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
[TBL] [Abstract][Full Text] [Related]
20. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
